Characteristics and Outcome of SARS-CoV-2 Infection in Cancer Patients.
Aged
Antiviral Agents
/ therapeutic use
COVID-19
/ diagnosis
COVID-19 Testing
/ methods
Comorbidity
Female
France
/ epidemiology
Hospitalization
/ statistics & numerical data
Humans
Intensive Care Units
/ statistics & numerical data
Male
Middle Aged
Neoplasms
/ diagnosis
Outcome Assessment, Health Care
/ methods
Pandemics
/ prevention & control
Registries
/ statistics & numerical data
Risk Factors
SARS-CoV-2
/ drug effects
Survival Analysis
COVID-19 Drug Treatment
Journal
JNCI cancer spectrum
ISSN: 2515-5091
Titre abrégé: JNCI Cancer Spectr
Pays: England
ID NLM: 101721827
Informations de publication
Date de publication:
Feb 2021
Feb 2021
Historique:
received:
22
05
2020
revised:
10
07
2020
accepted:
22
07
2020
entrez:
19
2
2021
pubmed:
20
2
2021
medline:
20
2
2021
Statut:
epublish
Résumé
Concerns have emerged about the higher risk of fatal coronavirus disease 2019 (COVID-19) in cancer patients. In this article, we review the experience of a comprehensive cancer center. A prospective registry was set up at Institut Curie at the beginning of the COVID-19 pandemic. All cancer patients with suspected or proven COVID-19 were entered and actively followed for 28 days. Among 9842 patients treated at Institut Curie between March 13 and May 1, 2020, 141 (1.4%) were diagnosed with COVID-19, based on reverse transcription polymerase chain reaction testing and/or computerized tomography scan. In line with our case mix, breast cancer (40.4%) was the most common tumor type, followed by hematological and lung malignancies. Patients with active cancer therapy or/and advanced cancer accounted for 87.9% and 68.9% of patients, respectively. At diagnosis, 78.7% of patients had COVID-19-related symptoms, with an extent of lung parenchyma involvement inferior to 50% in 95.8% of patients. Blood count variations and C-reactive protein elevation were the most common laboratory abnormalities. Antibiotics and antiviral agents were administered in 48.2% and 6.4% of patients, respectively. At the time of analysis, 26 patients (18.4%) have died from COVID-19, and 100 (70.9%) were cured. Independent prognostic factors at the time of COVID-19 diagnosis associated with death or intensive care unit admission were extent of COVID-19 pneumonia and decreased O COVID-19 incidence and presentation in cancer patients appear to be very similar to those in the general population. The outcome of COVID-19 is primarily driven by the initial severity of infection rather than patient or cancer characteristics.
Sections du résumé
BACKGROUND
BACKGROUND
Concerns have emerged about the higher risk of fatal coronavirus disease 2019 (COVID-19) in cancer patients. In this article, we review the experience of a comprehensive cancer center.
METHODS
METHODS
A prospective registry was set up at Institut Curie at the beginning of the COVID-19 pandemic. All cancer patients with suspected or proven COVID-19 were entered and actively followed for 28 days.
RESULTS
RESULTS
Among 9842 patients treated at Institut Curie between March 13 and May 1, 2020, 141 (1.4%) were diagnosed with COVID-19, based on reverse transcription polymerase chain reaction testing and/or computerized tomography scan. In line with our case mix, breast cancer (40.4%) was the most common tumor type, followed by hematological and lung malignancies. Patients with active cancer therapy or/and advanced cancer accounted for 87.9% and 68.9% of patients, respectively. At diagnosis, 78.7% of patients had COVID-19-related symptoms, with an extent of lung parenchyma involvement inferior to 50% in 95.8% of patients. Blood count variations and C-reactive protein elevation were the most common laboratory abnormalities. Antibiotics and antiviral agents were administered in 48.2% and 6.4% of patients, respectively. At the time of analysis, 26 patients (18.4%) have died from COVID-19, and 100 (70.9%) were cured. Independent prognostic factors at the time of COVID-19 diagnosis associated with death or intensive care unit admission were extent of COVID-19 pneumonia and decreased O
CONCLUSIONS
CONCLUSIONS
COVID-19 incidence and presentation in cancer patients appear to be very similar to those in the general population. The outcome of COVID-19 is primarily driven by the initial severity of infection rather than patient or cancer characteristics.
Identifiants
pubmed: 33604509
doi: 10.1093/jncics/pkaa090
pii: pkaa090
pmc: PMC7665636
doi:
Substances chimiques
Antiviral Agents
0
Types de publication
Journal Article
Langues
eng
Pagination
pkaa090Informations de copyright
© The Author(s) 2021. Published by Oxford University Press.
Références
JAMA. 2020 Mar 17;323(11):1061-1069
pubmed: 32031570
Ann Oncol. 2020 Aug;31(8):1065-1074
pubmed: 32442581
Ann Oncol. 2020 May;31(5):553-555
pubmed: 32201224
JAMA Oncol. 2020 Jul 1;6(7):1108-1110
pubmed: 32211820
Science. 2020 Jul 10;369(6500):208-211
pubmed: 32404476
Nature. 2020 Aug;584(7821):430-436
pubmed: 32640463
Bull Cancer. 2020 Jun;107(6):620-622
pubmed: 32389352
Lancet Oncol. 2020 Mar;21(3):335-337
pubmed: 32066541
JAMA Oncol. 2020 Jun 1;6(6):821-822
pubmed: 32275294
BMJ. 2020 Apr 29;369:m1735
pubmed: 32349991
JAMA. 2020 Apr 7;323(13):1239-1242
pubmed: 32091533
Ann Oncol. 2020 Jul;31(7):894-901
pubmed: 32224151
Lancet. 2020 Feb 22;395(10224):565-574
pubmed: 32007145
Cancer Discov. 2020 Jun;10(6):783-791
pubmed: 32345594
N Engl J Med. 2020 Apr 30;382(18):1708-1720
pubmed: 32109013
Lancet Oncol. 2020 May;21(5):633
pubmed: 32325021
Lancet Infect Dis. 2020 Jul;20(7):773
pubmed: 32171390
Crit Care. 2020 Apr 28;24(1):179
pubmed: 32345311
Lancet. 2020 Jun 20;395(10241):1907-1918
pubmed: 32473681
Nat Rev Immunol. 2015 Aug;15(8):486-99
pubmed: 26205583
Lancet. 2020 Feb 15;395(10223):497-506
pubmed: 31986264
Lancet. 2020 Mar 28;395(10229):1033-1034
pubmed: 32192578
N Engl J Med. 2020 Apr 23;382(17):e38
pubmed: 32268022
PLoS One. 2014 Jun 27;9(6):e101176
pubmed: 24972092
Lancet Oncol. 2014 Oct;15(11):e493-503
pubmed: 25281468
Ann Oncol. 2020 Aug;31(8):1088-1089
pubmed: 32330541
Lancet Oncol. 2020 Jun;21(6):750-751
pubmed: 32359403